Psilocybe natalensis and Related Naming Questions

Safety first

This page is about names and science, not use. It does not help anyone identify, obtain, grow or take any fungus, and a name or photo can never show that a mushroom is safe. If someone has swallowed an unknown mushroom or is in distress, call 911 (US) or Poison Help at 1-800-222-1222; see poisoning: what to do first. In the US, 988 reaches the Suicide & Crisis Lifeline.

Evidence labels: preclinical (cells/animals only), insufficient evidence, mixed, marketing claim. "Proper evidence not found" means we looked and found nothing usable.

What the name refers to

Psilocybe natalensis is listed by the Global Biodiversity Information Facility (GBIF) backbone as an accepted species in the family Hymenogastraceae, with the authority Gartz, D.A.Reid, M.T.Sm. & Eicker, published in 1995 in the journal Integration. [1] A laboratory paper describes it as a psilocybin-containing mushroom that grows in South Africa. [2]

Why the name is a naming question

Three separate findings show why "natalensis" on a label deserves caution.

• Genetic identification. In a 2025 study of 42 cultivated strains, the strains supplied as P. natalensis were identified as P. cubensis by DNA sequencing of the ITS region, and the authors noted that their chemical groupings matched the DNA identification better than the traditional appearance-based one. [3] This is one DNA region in one study of supplied strains. It does not by itself settle whether P. natalensis is a separate species, a variety, or a name used for cultivated P. cubensis lines.
• Unreliable specimen names in general. A 2022 re-examination of 94 museum Psilocybe specimens, using DNA barcodes, concluded that species identifications were largely unreliable apart from a few well-known species. It also noted a large amount of poor-quality or mislabeled sequence data in public databases. [4]
• A reference-material project. A 2026 paper describing one company's (Nammex) cultivation effort reports growing six Psilocybe species, including one named P. natalensis, with identity checked by appearance, microscopy and DNA sequencing. [5] Because the work comes from a company's own project, treat it as one data point and not independent confirmation.

Our reading: the accepted name exists in the taxonomy databases, but whether strains sold as P. natalensis are that species is mixed and unresolved in the sources we read. See commercial mushroom names and species identification and naming limits. For the species it was matched with, see Psilocybe cubensis.

Composition: what is and is not known

There is no typical psilocybin content for this name, and we do not give one. The 2026 reference-material paper reports measurements for six species by thin-layer chromatography, with psilocybin from 0.45% to 1.89% across them. The extremes belonged to other species, and the paper notes that storage method, stem versus cap, and developmental stage changed the results. [5] Fresh mushrooms stored in a freezer before freeze-drying had much less psilocybin and more psilocin in that study. [5] A 2022 study of museum specimens likewise found psilocybin and psilocin decay over time, with some specimens having none detectable. [4]

What research shows about health effects

Preclinical (cells/animals only). South African laboratory studies tested water and ethanol extracts of P. natalensis on cultured macrophage cells (the RAW 264.7 line); the extracts reduced several inflammation markers in a dish. [2] A later study on human macrophage-type cells tested water extracts of four mushrooms, including P. natalensis, with similar findings. [6] These results are from cells and cannot be transferred to people. A 2026 narrative review of extract studies notes that concerns about toxicity persist, especially at higher concentrations. [7]

Insufficient evidence for any human outcome. Proper evidence not found for human trials of P. natalensis; we searched PubMed for the species name and found cell studies and chemistry papers only.

Risks and legal context

General psilocybin risks (agitation, rapid heartbeat, confusion, vomiting, rare lasting perception changes) are described by NIDA and are not specific to this name. [8] See adverse effects and contraindications.

Laws change and this is not legal advice. The US federal Schedule I list (21 CFR 1308.11, read 2026-10-22) names psilocybin and psilocyn and covers material containing any quantity of a listed hallucinogen unless excepted. [9] We did not verify other jurisdictions; see psychedelic legal status by country.